When your biosimilar analytical data shows 1.4% high mannose against a 6% reference product specification, you face limited options: process temperature shifts that compromise titer, kifunensine supplementation that requires extensive regulatory justification, or 12-18 months to reclone and revalidate. Media supplementation offers an alternative pathway—tuning glycan profiles through formulation adjustments rather than cell line or process re-engineering.

In this episode, David Brühlmann presents the experimental development of a media supplementation strategy that achieved 2.8-fold increases in high mannose glycans across multiple CHO cell lines. Drawing from research published in the Journal of Biotechnology (2017, 252:32-42), the discussion covers the mechanism of raffinose-mediated glycan processing arrest, the experimental variables that initially obscured the effect, and the process development considerations for implementing media-based glycan tuning.

The episode examines N-glycan biosynthesis in CHO cells, regulatory comparability requirements for biosimilar glycosylation profiles, and the experimental framework for evaluating media supplementation as a glycan control strategy.

Highlights from the episode:

• The unexpected link between dietary raffinose and reduced athletic performance, and its connection to bioprocessing (01:11)
• A clear primer on the importance of glycosylation for biosimilar drugs and regulatory approval (02:43)
• Common challenges when glycan profiles don't match reference products, and why high mannose glycans matter (04:19)
• A review of industry strategies (temperature shifts, enzyme inhibitors, cell line reengineering) and their pitfalls (05:33)
• Mechanistic insights into how raffinose alters glycan processing in CHO cells (07:05)
• Key experimental findings on raffinose concentration, osmolality control, and practical lab troubleshooting (09:48)
• Application stories and regulatory considerations for implementing raffinose-based media adjustments (13:47)
• Closing thoughts on process optimization, regulatory impact, and what to expect in Part 2 (15:11)

Strategic insight:

Implementing raffinose as a media supplement is straightforward, regulatory-friendly, and cost-effective. It does not involve genetic engineering or enzyme inhibitors and is easily sourced as a GMP-grade material. For programs approaching submission with glycan comparability gaps, media-based tuning offers a process optimization pathway that maintains existing cell lines and manufacturing platforms while addressing critical quality attribute specifications.

Listen to this episode of the Smart Biotech Scientist Podcast to learn David’s best strategies for rapid, regulatory-friendly glycosylation control.

If you want to transform your glycoengineering workflow, keep an eye (and ear) out for the next episode of the Smart Biotech Scientist Podcast. Your path to regulatory success might be as simple as a pinch of raffinose.

Resources: Journal of Biotechnology, 2017, volume 252, pages 32 to 42

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Support the show